Mirum Pharmaceuticals, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +50.2%
EBITDA: —
EBIT: +8.1%
EPS: —
Free cash flow: —
Operating cash flow: —

Forward estimates

Revenue: +24.6%
EBITDA: +45.5%
EPS: +90.6%

Three-year CAGR

Revenue: +89.1%
EBITDA: +135.1%
EBIT: +74.7%
Net income: +73.4%
EPS: +74.6%
Free cash flow: +488.0%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.